Skip to main content

Table 2 Classification of patients according to the presence of AGS symptoms with potential sources of alpha-gal and their test results for sIgE to alpha-gal, n (%)

From: Diagnostic validity of specific immunoglobulin E levels to alpha-gal in alpha-gal syndrome: a cross-sectional analysis

 

Group 1

Group 2

Total

Population

   

Positive test

32 (97.1)a

7 (10.8)b

39 (39.8)

Negative test

1 (3.0)c

58 (89.2)d

59 (60.2)

Total

33 (100.0)

65 (100.0)

98 (100.0)

Women

   

Positive test

2 (66.7)a

2 (5.0)b

4 (9.3)

Negative test

1 (33.3)c

38 (95.0)d

39 (90.7)

Total

3 (100.0)

40 (100.0)

43 (100.0)

Men

   

Positive test

30 (100.0)a

5 (20.0)b

35 (63.6)

Negative test

0 (0.0)c

20 (80.0)d

20 (36.4)

Total

30 (100.0)

25 (100.0)

55 (100.0)

  1. Group 1: Patients with AGS symptoms after being exposed to potential sources of alpha-gal
  2. Group 2: Patients without AGS symptoms after being exposed to potential sources of alpha-gal
  3. aTrue positive: patients with AGS symptoms after exposure to a source of alpha-gal with values sIgE ≥ 0.1 KUA/L
  4. bFalse positive: patients without AGS symptoms after exposure to a source of alpha-gal with values sIgE ≥ 0.1 KUA/L
  5. cFalse negative: patients with AGS symptoms after exposure to a source of alpha-gal with values sIgE < 0.1 KUA/L
  6. dTrue negative: patients without AGS symptoms after exposure to a source of alpha-gal with values sIgE < 0.1 KUA/L
  7. AGS, Alpha-gal Syndrome; sIgE, specific IgE
Back to article page

Allergy, Asthma & Clinical Immunology

ISSN: 1710-1492

Contact us